Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction.

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own about ...

Alumis and Acelyrin have agreed to merge in an all-stock deal, creating a late-stage biopharmaceutical company focused on ...

Southern California drug developer in a deal that extends the combined companies' cash into 2027, months after it expects key ...

On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (Nasdaq: ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025, subject ...

Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction, creating a late-stage clinical biopharma company. The merged company will focus on ...